Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1
$599.00
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1
$599.00
A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.
SKU: N/A
Author: Datamonitor Healthcare
Publisher: Biomedtracker
Published: 02 October 2018
Number of pages:15
Formats:PDF
Report code:TL #10133
Highlights
Description
Highlights
“I kind of perceive [ALKS 5461] in my mind like the use of ketamine, obviously there is a wrong way to use it, and there is a right way to use it, so there is something in the NMDA receptor that has abuse potential, it also has treatment or salvaging potential, and I think the same way about the pathway that the ALKS agent has, there is a wrong way to approach that mechanism of action, and there is a right way to approach that mechanism of action.”
Drug Coverage
Abilify
ALKS 5461
BuSpar
Cymbalta
Esketamine
Fetzima
ketamine
Lexapro
Pristiq
Prozac
Rapastinel
Rexulti
SAGE-217
Seroquel
Travivo
Trintellix
Viibryd
Vraylar
Zulresso
Overview
A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.